Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Incyte corporation symbols : Nvs save search
MorphoSys AG Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-13 (Crawled : 23:00) - biospace.com/
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -0.23%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.07%
H: 0.09%
C: -0.7%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.66%
H: 4.19%
C: 3.13%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 0.22%
H: 0.22%
C: -0.93%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.03%
H: 1.47%
C: -0.72%
year update financial results
Checkpoint Inhibitors Market Forecast Reveals Impressive Growth With Focus on Novel Therapies and Regional Expansion
Published: 2024-02-12 (Crawled : 23:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 3.52%
H: 0.0%
C: -1.18%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: 0.06%
H: 2.34%
C: 2.29%
ALPMY | News | $9.47 -0.21% -1.11% 400K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.14%
H: 0.35%
C: 0.07%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.34%
H: 0.23%
C: -1.13%
JNJ | News | $148.53 -0.69% 0.18% 7.5M
|
Health Technology
|
| O: 0.7%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: 1.22%
H: 0.07%
C: -0.43%
LLY | News | $732.2 -1.81% -0.84% 1.7M
|
Health Technology
|
| O: -0.96%
H: 1.75%
C: 1.75%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
ZLAB | $15.66 3.57% 3.45% 430K
|
Health Technology
|
| O: -1.15%
H: 1.03%
C: -1.5%
VRTX | $400.66 -1.05% -1.06% 810K
|
Health Technology
|
| O: -0.28%
H: 0.49%
C: -0.32%
SNY | News | $46.61 -2.27% -2.21% 1.6M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
IPHA | $2.46 3.8% 4.05% 690
|
Health Technology
|
| O: -3.1%
H: 1.2%
C: -0.8%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 3.8%
H: 1.1%
C: -1.17%
BIIB | $201.99 4.56% 4.32% 2.7M
|
Health Technology
|
| O: -3.72%
H: 0.58%
C: -3.82%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.26%
H: 0.73%
C: -0.36%
ARGX | $375.0 -0.02% -0.02% 190K
|
Health Technology
|
| O: -2.3%
H: 1.65%
C: 0.83%
AMGN | News | $273.01 -0.19% -0.17% 1.5M
|
Health Technology
|
| O: 0.06%
H: 0.31%
C: -1.4%
expansion growth market
Incyte to Spotlight More Than 40 Hematology and Oncology Abstracts Including a Plenary Presentation at the ASH Annual Meeting
Published: 2023-11-02 (Crawled : 18:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -1.09%
H: 1.03%
C: 0.91%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 1.32%
H: 0.45%
C: -1.19%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 2.22%
H: 0.6%
C: -9.4%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -0.28%
H: 1.0%
C: -0.46%
presentation meeting
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs
Published: 2023-05-08 (Crawled : 15:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.11%
H: 0.72%
C: 0.3%
TCRR 4 | $1.48 3.38% 3.9M
|
Health Technology
|
| O: 6.91%
H: 1.49%
C: -2.49%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.03%
H: 0.17%
C: -1.19%
BNTX | News | $88.09 -0.45% -0.35% 230K
|
Health Technology
|
| O: 4.23%
H: 0.0%
C: -4.4%
ADAP | $1.085 -4.83% -5.07% 780K
|
Health Technology
|
| O: 1.43%
H: 2.11%
C: -1.41%
companies report cancer pancreatic global
Incyte Announces Data from Across its Oncology Portfolio will be Presented at the AACR Annual Meeting 2023
Published: 2023-03-14 (Crawled : 01:00) - biospace.com/
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -0.18%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.28%
H: 0.38%
C: 0.31%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 1.2%
H: 0.17%
C: -1.67%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: -1.79%
H: 3.39%
C: 3.39%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.18%
H: 1.06%
C: 0.94%
meeting
Incyte Reports 2022 Fourth Quarter and Year-end Financial Results, Provides 2023 Financial Guidance and Updates on Key Clinical Programs
Published: 2023-02-07 (Crawled : 13:00) - biospace.com/
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 2.27%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.13%
H: 1.01%
C: 0.89%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.29%
H: 0.86%
C: 0.72%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.19%
H: 1.15%
C: -2.27%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 1.6%
H: 0.0%
C: -0.59%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -1.02%
H: 0.29%
C: -3.04%
financial
Incyte Reports 2022 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-11-01 (Crawled : 12:00) - biospace.com/
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 1.13%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.68%
H: 1.05%
C: -0.23%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.47%
H: 0.09%
C: -0.55%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 1.07%
H: 2.51%
C: -0.11%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 3.1%
H: 1.8%
C: -0.6%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 1.59%
H: 7.26%
C: 1.89%
financial results
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-08-02 (Crawled : 12:00) - biospace.com/
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: -2.62%
H: 0.0%
C: 0.0%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -1.33%
H: 0.78%
C: -1.06%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.02%
H: 0.39%
C: -0.64%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.32%
H: 5.09%
C: 3.9%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: -3.37%
H: 3.3%
C: 0.92%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -4.39%
H: 0.2%
C: -1.92%
results
Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
Published: 2022-05-26 (Crawled : 11:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.11%
H: 0.0%
C: 0.0%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.33%
H: 0.0%
C: 0.0%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 3.5%
H: 2.14%
C: 0.19%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 1.26%
H: 0.95%
C: -1.13%
Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.39%
H: 0.15%
C: -1.07%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 3.73%
H: 0.09%
C: -3.98%
jakavi treatment disease approval
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.06%
H: 0.0%
C: 0.0%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 2.08%
H: 1.96%
C: -0.77%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 2.45%
H: 0.92%
C: -2.03%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 2.12%
H: 4.06%
C: 1.39%
results
Incyte Announces Positive CHMP Opinion for Ruxolitinib (Jakavi®) for the Treatment of Acute and Chronic Graft-Versus-Host Disease
Published: 2022-03-25 (Crawled : 14:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 1.14%
H: 0.0%
C: 0.0%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.33%
H: 0.29%
C: 0.01%
jakavi treatment disease positive chmp
Head and Neck Cancer Market worth $ 9.07 Billion by 2030 - Exclusive Report by InsightAce Analytic
Published: 2022-03-23 (Crawled : 11:00) - prnewswire.com
GLAXF | News | $19.54 -3.77% -14.18% 170
|
Health Technology
|
| O: 3.81%
H: 0.0%
C: -0.44%
AZNCF | News | $135.35 -3.53% -4.19% 400
|
Health Technology
|
| O: -4.55%
H: 6.28%
C: 6.28%
PFE | News 4 | $26.27 -0.19% 0.19% 18M
|
Health Technology
|
| O: -1.94%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.6%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% 1.25% 1.6M
|
Health Technology
|
| O: -0.87%
H: 0.0%
C: 0.0%
BMY | $48.86 -0.27% 1.0% 14M
|
Health Technology
|
| O: -0.55%
H: 0.0%
C: 0.0%
MGNX | $15.7 -3.27% -3.38% 520K
|
Health Technology
|
| O: -1.31%
H: 3.88%
C: -0.67%
KURA | News | $18.75 0.11% 0.16% 820K
|
Health Technology
|
| O: -1.34%
H: 0.12%
C: -2.6%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.04%
H: 0.08%
C: -1.26%
AZN | News | $71.2 0.49% 0.46% 5.4M
|
Health Technology
|
| O: -0.31%
H: 1.85%
C: 1.55%
ADXS | $0.54 12.48% 270
|
Health Technology
|
| O: -1.64%
H: 8.33%
C: 0.0%
CVM | $1.46 -0.68% 0.0% 74K
|
Health Technology
|
| O: -0.92%
H: 2.31%
C: -3.47%
report cancer market
New data at ASH spotlight Novartis recently approved Scemblix®, next-generation CAR-T platform and expanding hematology portfolio
Published: 2021-11-04 (Crawled : 15:15) - globenewswire.com
NVSEF | News | $96.0 0.94% 6.88% 0
|
Health Technology
|
| O: 0.18%
H: 0.0%
C: -0.89%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.06%
H: 0.28%
C: 0.18%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 2.41%
H: 0.0%
C: 0.0%
ema car-t platform
Incyte Reports 2021 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-11-02 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 0.49%
H: 0.56%
C: -0.07%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.3%
H: 0.15%
C: -0.4%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 2.7%
H: 1.01%
C: 0.85%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: 3.75%
H: 1.22%
C: 1.22%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -1.93%
H: 0.19%
C: -3.14%
financial results results
Incyte Announces FDA Approval of Jakafi® (ruxolitinib) for Treatment of Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-09-22 (Crawled : 18:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.17%
H: 0.08%
C: -0.47%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -3.87%
H: 1.0%
C: -4.83%
disease treatment fda fda approval approval
Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-08-03 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: -0.6%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.3%
H: 0.17%
C: 0.17%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: 0.55%
H: 1.32%
C: 1.03%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: -2.43%
H: 0.88%
C: 0.44%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -0.7%
H: 0.31%
C: 0.04%
financial results results
Incyte Announces U.S. FDA Has Extended the sNDA Review Period for Ruxolitinib (Jakafi®) in Chronic Graft-Versus-Host Disease (GVHD)
Published: 2021-06-08 (Crawled : 12:00) - biospace.com/
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: 0.84%
H: 0.01%
C: -0.81%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.9%
H: 0.49%
C: -1.25%
disease fda
Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer
Published: 2021-05-19 (Crawled : 22:00) - prnewswire.com
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.46%
H: 1.21%
C: 0.78%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: 0.12%
H: 3.3%
C: 2.08%
cancer breast cancer
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs
Published: 2021-05-04 (Crawled : 12:00) - biospace.com/
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: -0.12%
H: 0.0%
C: -1.25%
NVS | News | $98.35 1.1% 0.69% 2.1M
|
Health Technology
|
| O: -0.82%
H: 0.28%
C: -0.06%
XNCR | $19.05 3.7% 3.57% 760K
|
Health Technology
|
| O: -0.96%
H: 0.0%
C: -5.61%
MOR | News | $18.05 0.06% 0.17% 130K
|
Health Technology
|
| O: -4.71%
H: 0.33%
C: -2.65%
INCY | $51.74 0.17% 0.14% 1.6M
|
Health Technology
|
| O: -2.37%
H: 2.04%
C: -2.95%
financial results results
Gainers vs Losers
| 61% | 39% |
Top 10 Gainers
CSSE 4 | $0.4253 179.25% 64.77% 210M
|
Consumer Services
BOF | $2.08 77.78% 41.21% 110M
|
ILAG | $0.54 12.27% 40.62% 3.7M
|
LICN | $0.999 78.39% 40.49% 15M
|
AMST | $3.4 70.0% 39.58% 70M
|
Technology Services
MTC | $3.6 60.71% 38.04% 9.1M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.458 14.5% 30.92% 91K
|
Health Services
MULN | News | $3.77 38.1% 27.78% 13M
|
Information
RILY | $29.75 36.97% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.